IBJNews

UPDATE: Pipeline challenges force Lilly restructuring moves

Back to TopCommentsE-mailPrintBookmark and Share

Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges by launching innovative new medicines.

Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the company’s business units ups the ante on that bet—while indicating that it isn’t working yet.

In Lechleiter’s tenure, the Indianapolis-based drugmaker has abandoned three late-stage drugs and waited an extra year to win U.S. approval for the one new drug it did launch, the blood thinner Effient.

In little more than two years, Lilly will lose most of the $4.7 billion in annual revenue from its bestselling drug Zyprexa, as cheaper generic copies hit the market. And in the following three years, Lilly will lose patent protection on four more drugs, representing another $7.2 billion in annual revenue.

Lilly had $20 billion in total revenue last year. It hopes to shave $1 billion mainly by reducing its worldwide work force from 40,500 to 35,000.

“We came to the conclusion that we need to make more significant changes,” Lechleiter said while discussing the review process that led to today’s announced changes. He added, “The terms of engagement are changing. The bar is rising.”

Lilly officials broke the news of the changes to the company’s employees at 8:30 a.m. Lilly’s stock price rose on the news, climbing as much as 1.6 percent, to $33.33 per share. The company’s shares are still down 17 percent for the year and have been treading water since March.

Lechleiter said he did not know how many of the job cuts would occur in central Indiana or what types of jobs would be cut. But, with about 13,000 employees in the Indianapolis area, he acknowledged the largest chunk of reductions would likely come here.

The cuts represent a 13.5-percent reduction to Lilly’s total work force, which, if applied locally at the same percentage, would eliminate roughly 1,700 area jobs.

The job cuts will be made after Lilly restructures the company into five business units, with the goal of bringing new medicines to market faster. The units will be in animal health, cancer, diabetes, emerging markets and established markets, which will include the United States and Europe, as well as Lilly’s bestselling drugs. Lilly will also launch a new drug-development initiative, called the Development Center of Excellence, to speed drug development in later stages of testing.

Lechleiter said the changes would help Lilly get through its lean years and respond to the increasing pressures it faces from health care reform and pricing demands from governments and insurers across the globe.

"We're going to see better decision-making, much more opportunity seeking," Lechleiter said, adding that Lilly would be "a company that is more focused and competitive than ever."

The restructuring and job cuts are similar to things tried by other pharmaceutical firms. For example, New York-based Pfizer Inc. announced a year ago it would restructure its research units to focus on five areas: Alzheimer's, cancer, mental health, pain and diabetes. It later said it would cut 800 scientists.

“Everybody’s sort of done these things in some form or another. Nobody’s really found the magic bullet,” said Les Funtleyder, a health care stock analyst at Miller Tabak & Co. in New York. He called Lilly’s moves “prudent,” but said it’s unclear if they will really help bring medicines to market faster.

New products, he said, are the ultimate test of a company’s long-term value.

“It’s sort of an acknowledgement on Lilly’s part—as it is with some of he other pharmas—that they’re going to be losing revenue that’s not going to be replaced by their pipeline,” Funtleyder said.

Lilly’s new business units will launch Jan. 1. Their leaders will be:

— Cancer: John Johnson, CEO of ImClone Systems, which Lilly bought in 2008.

— Diabetes: Enrique Conterno, president of Lilly USA.

— Animal health: Jeff Simmons, who already leads this unit, called Elanco.

— Emerging markets: Jacques Tapiero, president of Lilly’s intercontinental region.

— Established markets: Bryce Carmine, Lilly’s executive vice president of global marketing and sales.

— Development Center of Excellence: Dr. Tim Garnett, Lilly’s chief medical officer, and Thomas Verhoeven, Lilly’s senior vice president for global product development.

Lilly now has more than 60 molecules in its development pipeline, but has struggled recently to actually bring them to market. Just this year, Lilly abandoned drugs designed to treat multiple sclerosis and osteoporosis.

In 2008, Lilly canceled work on an inhaled version of insulin for diabetes. In July, the U.S. Food and Drug Administration approved Effient. Lilly launched the drug last month. But because bleeding risks led the FDA to put a black box warning on Effient’s label, analysts no longer expect Effient to rack up huge sales. Many expect it to bring Lilly less than $1 billion a year by 2013.

“I just don’t see it taking the world by storm,” Funtleyder said.

ADVERTISEMENT

  • medsearch wrote: "... reform will cost 500,000 jobs in health care." I present to you that this is a GOOD thing. We need to cut costs in health care. How many of us have seen the useless blonde pharma reps circulating in our doctors office's w/ bagels? Is this really the best use of our pharma dollars? I say cut those jobs and many more. Lilly proposes to cut 5500 jobs and save $1B. If we cut 500,000 jobs, then using Lilly numbers, we've cut $90trillion in expenses from our bloated health care system. Too many Benz's in the Lilly parking garage. Too many granite bathroom countertops in LLY Corp. Time for pharma & health care to get realistic. Time for the US to stop paying 3x the price of drugs that Europe does. Some in Obamacare GET IT. Some at gorilla may not.
  • I'm a former Lilly employee. You wrote: "City Doled Out $1.6 Billion In Incentives To Eli Lilly Shouldn't Lilly be held accountable for failing to fulfill its promise to the City and asked to repay its incentives?" Unfortunately, this is going on all over the country. The "city" didn't pay this, taxpayers did. Taxpayers need to stop funding big corps. This wasn't Lilly's fault, it's OUR fault for electing reps who capitulate. Lilly's made it's best effort to fulfill promise to city, but unfortunately the drug appv'ls didn't come.
  • Lilly has to downsize in Indiana, and elsewhere, to pay for the huge growing investment in China. They have a major R&D center there, subcontract to many other Chinese companies, and even perform much of their clinical trials there. They had this "restructuring" planned all along, and certainly can't blame it on healthcare reform (real or perceived) or pipeline. Lilly was a major player (along with the PHRMA) in successfully lobbying Congress and the President to ensure continued profits for big pharma. Don't buy into the massive PR scam that Lilly and other companies are running. www.hoosiercontrarian.com
  • City Doled Out $1.6 Billion In Incentives To Eli Lilly

    Shouldn't Lilly be held accountable for failing to fulfill its promise to the City and asked to repay its incentives?

    http://advanceindiana.blogspot.com/2009/09/city-doled-out-16-billion-in-incentives.html

    • As a former Lilly sales representative, and current president/CEO of Gorilla Medical Sales, LLC, a leading medical sales job board, I totally understand the downsizing going on at Lilly. Lilly is joined by most of Big Pharma is cutting jobs.

      What the Obama reformists do ot understand, is that reform will cost 500,000 jobs in health care. In my industry, medical device sales, we have already lost over 20,000 jobs in medical sales as companies position themselves for the new selling environment. To learn more about the impact of Obamacare on jobs in Indiana, visit our blog at http://www.gorillamedicalsales.com

      Post a comment to this story

      COMMENTS POLICY
      We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
       
      You are legally responsible for what you post and your anonymity is not guaranteed.
       
      Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
       
      No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
       
      We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
       

      Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

      Sponsored by
      ADVERTISEMENT

      facebook - twitter on Facebook & Twitter

      Follow on TwitterFollow IBJ on Facebook:
      Follow on TwitterFollow IBJ's Tweets on these topics:
       
      Subscribe to IBJ
      1. I am also a "vet" of several Cirque shows and this one left me flat. It didn't have the amount of acrobatic stunts as the others that I have seen. I am still glad that I went to it and look forward to the next one but I put Varekai as my least favorite.

      2. Looking at the two companies - in spite of their relative size to one another -- Ricker's image is (by all accounts) pretty solid and reputable. Their locations are clean, employees are friendly and the products they offer are reasonably priced. By contrast, BP locations are all over the place and their reputation is poor, especially when you consider this is the same "company" whose disastrous oil spill and their response was nothing short of irresponsible should tell you a lot. The fact you also have people who are experienced in franchising saying their system/strategy is flawed is a good indication that another "spill" has occurred and it's the AM-PM/Ricker's customers/company that are having to deal with it.

      3. Daniel Lilly - Glad to hear about your points and miles. Enjoy Wisconsin and Illinois. You don't care one whit about financial discipline, which is why you will blast the "GOP". Classic liberalism.

      4. Isn't the real reason the terrain? The planners under-estimated the undulating terrain, sink holes, karst features, etc. This portion of the route was flawed from the beginning.

      5. You thought no Indy was bad, how's no fans working out for you? THe IRl No direct competition and still no fans. Hey George Family, spend another billion dollars, that will fix it.

      ADVERTISEMENT